Skip Navigation


The European Journal of Public Health Advance Access originally published online on February 12, 2009
The European Journal of Public Health 2009 19(3):254-259; doi:10.1093/eurpub/ckp005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/3/254    most recent
ckp005v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Chodick, G.
Right arrow Articles by Ashkenazi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chodick, G.
Right arrow Articles by Ashkenazi, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Public Health Association. All rights reserved.

Infectious Diseases

Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel

Gabriel Chodick1,2, Orith Waisbourd-Zinman3, Varda Shalev1,2, Ehud Kokia1,2, Mordechai Rabinovich1 and Shai Ashkenazi2,3

1 Maccabi Healthcare Services, 27 Ha'Mered Street, Tel–Aviv, Israel
2 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3 Schneider Children's Medical Center, 14 Kaplan Street, Petach-Tikva, Israel

Correspondence: Gabriel Chodick, PhD, Medical Informatics, Maccabi Healthcare Services, 27 Ha'Mered Street, Tel Aviv 68125, Israel, tel: 972-3-7952430, fax: 972-3-5141570, e-mail: hodik_g{at}mac.org.il

Received August 6, 2008 , accepted January 9, 2009

Background: Rotavirus is a common cause of acute gastroenteritis in children under 5 years of age. Two effective vaccines against rotavirus gastroenteritis were recently licensed in many countries throughout the world. The study aimed to investigate the cost effectiveness of vaccinating an Israeli birth cohort of 143 500 children. Methods: The cost-effectiveness analysis was determined using a decision analytical model, based on evidence-based estimates of the medical burden of rotavirus gastroenteritis in Israel. Results: According to our model, a routine rotavirus immunization program using Rotarix® and RotaTeq® would prevent 17 801 and 13 288 office visits and 645 and 535 hospitalizations every year, respectively. When direct healthcare costs and societal costs are taken into account, the incremental cost-effectiveness ratio per gained QALY for Rotarix® and RotaTeq® are $10 995 and $30 674, respectively. Conclusion: Rotavirus vaccination can be considered a cost-effective intervention in Israel, depending on the precise vaccine price.

Keywords: rotavirus, cost effectiveness, immunization


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.